Preclinical Production

You have a vial of mammalian cells with the gene of your target drug and you are eager to produce pre-clinical material for toxicology studies.  Look no further.  At Laureate, we have built a brand new pilot plant facility to accelerate the production of your pre-clinical material.  The plant is now available for engineering runs and pre-clinical production.

We have designed the pilot plant to accommodate process development, production and purification of preclinical proteins. The pilot plant is isolated from our main manufacturing area and features two separate production suites and two expanded purification suites to support pre-clinical production of protein based products from mammalian cells. The suites mimic our already existing cGMP production facility and equipment to facilitate a direct, seamless scale-up from development to cGMP production. The pilot plant has stainless steel, stirred-tank bioreactors and disposable, single-use bioreactors – the same technologies we use in our larger scale cGMP-manufacturing facility. The purification suites feature the same process chromatography and filtration technologies we use in the cGMP facility. With the new pilot plant in operation, we can accelerate manufacturing of pre-clinical material and save several months of critical product development time.

Pilot Plant equipment:

Stirred-Tank

  • 1 x 300L (200L Vw)
  • 1 x 75L (~50L Vw)
  • 2 x 7L (5L Vw)
  • 2 x 3L (2L Vw)

WAVE Bioreactor®

  • 1 x System 200
  • 2 x System 20/50
  • 1 x System 2/10

Purification

  • 2 x 3L/min chromatography skid ÄKTA™ Process GE Healthcare
  • 200L CUNO filtration skid
  • Cross-flow filtration skid 30L/min – Uniflux™ GE Healthcare

Reasons why you should use our pilot plant:

  • You don’t have to wait for full cell line qualification. We need only minimal qualification (sterility and mycoplasma testing) for cells entering the pilot plant
  • We can run pilot and engineering runs in the shortest time possible
  • We’ve designed the pilot plant suites to mimic our existing cGMP production facility and equipment so that we can seamlessly transfer the product/project from pre clinical development to cGMP production
  • You save 2-3 months of critical product development time

Please give us a call to discuss your
preclinical production needs

201 College Road East
Princeton, New Jersey 08540
Contract Services: 1.609.919.3400
Main Office: 1.609.919.3300
Fax: 1.609.520.3963
Email: info@lbios.com
www.lbios.com

Pharmacy News

Detecting Fake Medicines | Trust Pharmacy Guide for Consumers

New drugs are invented every year. Their total cost is approximately $27 million – about 1% of the entire pharmaceutical market. Thus, the risk of buying a counterfeit from a pharmacy is very small. However, there is also a factory defect or poor-quality drugs that simply will not cure a patient. MLST Trust Pharmacy has been working in the pharmaceutical market for over 10 years and has close cooperation with…

What Is A Conventional and Online Pharmacy in the USA and Canada?

Retailing pharmaceuticals in the USA is a rather huge market. Most pharmacies in the United States are private. Every person can buy absolutely any product in the US pharmacy, even if this does not apply to medications. American pharmacies occupy a fairly large area, consist of two zones – the zone for dispensing drugs and a self-service zone. In the states, almost all medications are sold only by prescription. Only…

Laureate and ARIUS Cooperation

Princeton, NJ and Paris, France, March 27, 2008: Laureate Pharma, Inc., a full-function facility of biopharmaceutical development and protein manufacturing, claimed nowadays that it has signed a contract with Cytheris SA, a clinical phase of biopharmaceutical facility oriented on trials and development of new treatment for immune stimulation. According to the contract, Laureate will produce Cytheris’ lead product candidate, Interleukin-7 (IL-7), a complete glycated recombinant human protein and crucial growth-stimulating…

Laureate Announces Second Manufacturing Agreement with Cytheris

Princeton, NJ and Paris, France, March 27, 2008: Laureate Pharma, Inc., a full-function facility of biopharmaceutical development and protein manufacturing, claimed nowadays that it has signed a contract with Cytheris SA, a clinical phase of biopharmaceutical facility oriented on trials and development of new treatment for immune stimulation. According to the contract, Laureate will produce Cytheris’ lead product candidate, Interleukin-7 (IL-7), a complete glycated recombinant human protein and crucial growth-stimulating factor for…

Laureate Pharma Agreement with Alopexx Pharmaceuticals

Laureate To Manufacture Alopexx’s Product Candidate On April 10, 2008, Laureate Pharma, Inc., a large company engaged in biopharmaceutical development and protein production reported that it has concluded a contract manufacturing agreement with Alopexx Pharmaceuticals on the production of Alopexx’s mAb F598 antibody under cGMP conditions. This antibody will be used in clinical trials and also for fighting Staphylococcus aureus infections. The details of the agreement were not announced. “We are happy that Laureate…

Laureate Pharma Company – Press Release

FOR IMMEDIATE RELEASE Laureate Pharma Launches New Contract Manufacturing Venture Company offers services for development and manufacture of biopharmaceuticals and sustained-release products Princeton, NJ – May 21, 2002 – Laureate Pharma Company announces the launch of contract manufacturing services at its two sites in New Jersey. Biopharmaceutical development and manufacturing services will be provided at a cGMP manufacturing facility in Princeton, NJ. Services related to sustained release microsphere products will…

Laureate Pharma Extends its Agreement with Cytogen for Manufacture of PROSTASCINT®

Princeton, NJ – October 25, 2006: Laureate Pharma, Inc. announced today that it has renewed its agreement with Cytogen Corporation for the cGMP manufacture of ProstaScint®, Cytogen’s proprietary monoclonal antibody immunoconjugate that is used for imaging in patients diagnosed with prostate cancer. Under the agreement, Laureate will provide cGMP protein production, purification, conjugation of Cytogen’s proprietary linker chelator and aseptic filling services to support Cytogen’s commercial ProstaScint® requirements. Terms of…

Laureate Pharma & DrugAbuse Sciences – Press Release

FOR IMMEDIATE RELEASE Laureate Pharma and DrugAbuse Sciences Announce Commercial Manufacturing Services Agreement. Princeton, NJ – June 24, 2002 – Laureate Pharma L.P. and DrugAbuse Sciences, Inc. announce the initiation of a contract manufacturing agreement related to a sustained release microsphere product. Under the agreement, Laureate Pharma will provide manufacturing services for DrugAbuse Sciences’ Naltrexone Depot product, currently in clinical trials. Terms of the agreement were not disclosed. “We are…

LAUREATE PHARMA COMPLETES SALE OF TOTOWA, NJ OPERATIONS TO DISCOVERY LABORATORIES FOR $16.0 MILLION

Laureate’s Bioprocessing Facility at Princeton, NJ to be Expanded Princeton, NJ – January 3, 2006 – Laureate Pharma, Inc., a wholly-owned subsidiary of Safeguard Scientifics, Inc. (NYSE: SFE), announced today that it had completed the previously announced sale of its Totowa, NJ operations to Discovery Laboratories, Inc. (NASDAQ: DSCO) for $16.0 million in cash. Laureate Pharma, a provider of bioprocessing services to pharmaceutical and biopharmaceutical companies, conducts its principal operations…

Laureate Biopharma Appoints Ann M. Daus, Ph.D. Vice President, Quality

– Leads implementation of Laureate’s strategic quality plan – PRINCETON, N.J., March 16, 2011 — Laureate Biopharmaceutical Services, Inc., a full-service biopharmaceutical contract development and manufacturing organization, today announced the appointment of Ann M. Daus, Ph.D, as Vice President, Quality. Dr. Daus will lead the implementation of Laureate’s strategic quality plan, recruit new leaders to supplement the quality management team, lead the strategic expansion of testing services and improve companywide…

Laureate Pharma Honored as Emerging Life Sciences Company of the Year

Laureate recognized for its business growth, leadership team and service innovation by the Eastern Technology Council Princeton, NJ, November 20, 2008: Laureate Pharma, Inc., a full-service biopharmaceutical development and protein production company, today announced that it has been named the “Emerging Life Science Company of the Year” by The Eastern Technology Council, the largest technology and life sciences trade association in the greater Philadelphia, PA region. The company was honored…

Laureate Pharma Announces Manufacturing Agreement with Alopexx Pharmaceuticals, LLC

Laureate To Manufacture Alopexx’s Product Candidate Princeton, NJ, April 10, 2008: Laureate Pharma, Inc., a full-service biopharmaceutical development and protein production company, today announced that it has entered into a cGMP contract manufacturing agreement with Alopexx Pharmaceuticals, LLC. According to the agreement, Laureate will produce Alopexx’s mAb F598 antibody under cGMP conditions. This antibody is planned for use in clinical trials, and later for commercial production for the treatment and…